Morgan Stanley Maintains Overweight on United Therapeutics, Raises Price Target to $318
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn maintains an Overweight rating on United Therapeutics (NASDAQ:UTHR) and raises the price target from $316 to $318.
August 04, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics' price target has been raised from $316 to $318 by Morgan Stanley, which maintains an Overweight rating on the stock.
The raised price target by Morgan Stanley indicates a positive outlook for United Therapeutics. This could potentially lead to an increase in the stock's price in the short term as it signals the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100